Isolation of (−)-cyatha-3,12-diene, a common biosynthetic intermediate of cyathane diterpenoids, from an erinacine-producing basidiomycete, Hericium erinaceum, and its formation in a cell-free system
isolated for the first time from an erinacine-producing basidiomycete, Hericium erinaceum YB4-6237. This hydrocarbon had been formulated by Ayer et al. as a common biosynthetic intermediate of cyathane diterpenoids. Its stereo-structure, including the absolute configuration, has been unambiguously confirmed by its semi-synthesis from erinacine P, and its cell-free conversion from all-trans-geranylgeranyl
Isolation of erinacine P, a new parental metabolite of cyathane-xylosides, from Hericium erinaceum and its biomimetic conversion into erinacines A and B
作者:Hiromichi Kenmoku、Takeshi Sassa、Nobuo Kato
DOI:10.1016/s0040-4039(00)00601-8
日期:2000.6
A new cyathane-xyloside, erinacine P, was isolated from mycelia of basidiomycetous Hericium erinaceum YB4-6237 in a shaken culture. Since its aglycon closely resembles typical cyathane diterpenoids such as cyathins and cyathatriols in its substitution pattern, this glycoside seems to be an important metabolite in the biosynthesis of erinacines and striatins. In fact, according to our biogenesis studies, erinacine P can be successfully converted chemically into erinacine B and, further, to erinacine A under mild conditions. (C) 2000 Elsevier Science Ltd. All rights reserved.
COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
申请人:CaaMTech, LLC
公开号:US20190142851A1
公开(公告)日:2019-05-16
This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
申请人:CAAMTECH, INC.
公开号:US20210346346A1
公开(公告)日:2021-11-11
Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
Erinacine Q, a New Erinacine from<i>Hericium erinaceum</i>, and its Biosynthetic Route to Erinacine C in the Basidiomycete
spectrometry and a chemical derivation from erinacine P (2) determined the compound to be a derivative in which the formylgroup of erinacine P had been reduced to the hydroxymethylgroup. To clarify the biosynthetic relationship between erinacine Q and the others, [1'-13C]erinacine Q ([1'-13C]-1) was chemically derived from [1'-13C]erinacine P ([1'-13C]-2) which had been prepared by feeding [1-13C]-D-glucose